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Dentine Hypersensitivity is a common clinical condition, albeit of a low severity, and various in vitro 
and in vivo studies have been performed to test various approaches in managing the condition. This 
review investigates the use of bioactive glasses and their efficacy in treating Dentine Hypersensitivity. 
Significant progress was observed in the introduction of bioactive glasses in previous toothpaste 
formulations due to its ability to produce a Hydroxyapatite-like layer. Nevertheless, the results of the 
present review would suggest that a higher quality evidence was required to sufficiently support the use 
and effectiveness of bioactive glasses in treating Dentine Hypersensitivity. This observation is 
particularly pertinent in the absence of evidence relating to the effect of abrasivity of the glasses as well 
as the ability of strontium incorporation into the glasses. And the exact loading of the glass into 
dentifrice formulations. Overall, in vitro studies do appear to demonstrate that bioactive glass 
formulations may be an effective material to occlude dentine tubules which may in turn, reduce the 
fluid flow within the dentinal tubules and subsequently help manage Dentine Hypersensitivity.  
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Introduction 
Dentine Hypersensitivity (DH) is a common clinical condition which may affect up to 74% of the 
population (Talioti et al., 2014). DH can be defined as a “short, sharp pain arising from exposed dentine 
in response to stimuli typically thermal, evaporative, tactile, osmotic or chemical and which cannot be 
ascribed to any other form of dental defect or pathology” (Holland et al. 1997). The condition is 
generally prevalent in the age 20-49 year group and may affect the facial or buccal surfaces of incisors, 
premolars and canines, although molars may also be affected. From a clinical perspective the loss of 
the overlying enamel and/or cementum may be due to a number of aetiological factors usually in 
combination, such as Abrasion, Attrition, Abfraction, Erosion, Gingival recession, effects of 
periodontal disease and/or effects of periodontal treatment (Gillam & Orchardson 2006). According to 
Miglani et al., 2010 DH may also affect up to 90% of patients following non-surgical and surgical 
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periodontal treatment. It is evident however that despite experiencing varying degrees of discomfort 
most patients did not seek treatment from their Dentist or use a desensitising toothpaste to alleviate DH 
(Gillam et al., 2002, Gillam 2013). Currently treatment approaches are based on the Brännström 
hydrodynamic theory (West et al., 2013) which required the dentine tubules to act as a capillary bore 
with the tubule open to the oral environment. According to this theory a stimuli (e.g.., cold air) resulted 
in the movement of the fluid within the dentine tubules which can be sensed by mechanical receptors 
near the pulp which in turn transmits the stimulus via Aδ and A β fibres triggering a short, sharp pain 
(Brännström and Aström, 1972). A number of in vivo and in vitro studies have reported that in subjects 
who have either been identified as responding/not responding to a stimulus (through a clinical 
examination) that there was a significant difference in the appearance of the surfaces of the teeth. For 
example, die replicas from the clinical impressions of the teeth identified as being sensitive, when 
viewed under SEM indicated that there were up to 8x more patent tubules per unit area in hypersensitive 
dentine compared to non-sensitive dentine. These tubules also had a wider aperture (X2) compared to 
non- sensitive dentine (Joshi et al., 2013).  According to West et al., (2013) there was no evidence of 
any differences between coronal and radicular dentine hypersensitivity, although it was reported that in 
cervical root dentine there were fewer tubules with narrower apertures compared to mid coronal dentine 
[6]. Joshi et al., (2013) also reported that the hydraulic conductance of coronal dentine was much higher 
than in radicular dentine. The evidence from conducting in vitro hydraulic conductance measurements 
would suggest that successfully occluding the dentinal tubules would reduce the dentinal fluid flow. 
Although there a number of professionally applied and At-Home products that are available for the 
treatment of DH, there is no current acceptance as to a gold standard product to treat DH (Gillam et al. 
2013). More recently there has been renewed interest in the use of bioactive glass initially developed 
by Hench (1969, 1972) to incorporate into toothpaste formulations. The aim of this review was to 
evaluate the available published literature to determine whether there is sufficient evidence for the 
effectiveness of bioactive glass formulations in the treatment of DH. 
The discovery of bioactive glasses by Hench (1969) introduced novel synthetic materials that were 
capable of bonding to living tissues (Hench et al., 1972). Prior to this point, synthetic materials were 
designed to interact as little as possible with the human body and this often resulted in the formation of 
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a non-adherent fibrous layer which encapsulated the implanted material (Hench, 2013). Hench 
subsequently defined bioactive materials as those materials which may instigated a biological response 
at the interface of the material with a subsequent bond forming between the tissue and material. The 
key differences between bioactive glasses (BG’s) and traditionally soda-lime glasses lie in 3 main 
features namely 1) Less than 60 mol% of Silica, 2) High levels of Na2O and CaO, 3) High CaO/P2O5 
ratio (Shi, 2004). The original Bioglass® composition known as 45S5 was developed as a bone 
substitute and not as toothpaste formulation and contained 45% SiO2, 24.5% Na2O, 24.5% CaO, and 
6% P2O5.  According to Hench (1998) there are two main classifications of bioactive glasses (Table 1). 
 Table 1 Classification of BG’s (Hench; 1998)  
Class A Bioactive glasses Results in osteoconduction and osteoproduction. Binds to both soft 
and hard tissues. 
Class B Bioactive glasses Osteoconductive and only able to bind to hard tissues and not soft 
tissues.  
 
It was previously reported that not only does Bioglass® bind to bone but it also facilitates the 
regeneration of bone. Initially the bone substitute was implanted into humans as a replacement for the 
ossicles of the middle ear and was subsequently used as a material to repair bone defects eventually 
including those caused by periodontitis as well (Ali et al., 2014). There are four main methods by which 
genes involved with osteoblastic proliferation, differentiation, and cell to cell adhesion are upregulated 
namely: surface chemistry, topography, rate and type of dissolution ions and shear stress at the interface. 
As a result the rates of osteogenesis, angiogenesis, chondrogenesis, and differentiation of mesenchymal 
stem cells are increased. However, more advanced studies are required to fully appreciate the effect(s) 
of the bioactive glass on cell gene expression (Kaur et al., 2013). Although an increase in the 
transcription rates of a gene may be recorded for example of vascular endothelial growth factor, its 
physiological relevance is, however not fully known. Moreover, increased expression does not 
inherently correspond to increased protein production since post-translational mechanisms may result 
in a different culmination to that expected.  
Further advantageous features of bioactive glasses include antimicrobial properties which may 
inhibit bacterial growth at the site of implantation, and further oral applications include pulp capping, 
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sinus obliteration, repair of orbital floor fracture, coating for dental implants, topical endodontic 
disinfectants as well as being used in air-abrasion(Ali et al., 2012; Hench, 2006). 
Therapeutic ions, drugs and growth factors  
The original 45S5 Bioglass® contained 45% SiO2, 24.5% Na2O, 24.5% CaO, and 6% P2O55, however, 
subsequently more research has been conducted into incorporating various therapeutic ions, drugs and 
growth factors into the glass structure. Table 2 outlines a variety of products that have been incorporated 
into the glass structure to provide a beneficial effect (Ali et al., 2012; Ali et al., 2014). 
Table 2 Ion, Drug or Growth Factor and their Effects 
Ion, Drug or Growth Factor Effect 
Fluoride Formation of Fluorapatite which is more 
chemically stable than HCA at lower pH values 
and so more acid resistant. Fluoride containing 
BG result in increased alkaline phosphatase 
activity, an indication of increased bone 
mineralisation. Nevertheless, low fluoride 
containing bioactive glasses demonstrated the 
greatest cell proliferation according to 
Gentleman et al., 2013. 
 
Inhibits bacterial enzymes. 
 
Stimulates osteoblasts at a concentration of 25–
500 ng ml−1, whilst over 500 ng ml−1 inhibits 
osteoblast activity.  
Strontium Improves demineralized dentine mineral density. 
 
Increases osteoblast activity and inhibits 
osteoclast activity.  
P2O5 Favours FAP formation instead of CaF2.  
 
Assists in the maintenance of network 
connectivity. 
Zinc Anti-inflammatory and anti-microbial. 
 




Lithium Promotes osteogenesis and cementogenesis 
 
Copper Anti-bacterial and promotes osteogenesis and 
angiogenesis 
 
Iron Promote osteogenesis 
 








Doxorubicin Anti-cancer drug.  
 
Inhibits activity of osteosarcoma cells. 
 
Additionally, the BG’s are anti-bacterial in nature due to the pH rise associated with cation 
release during the surface reactions. For example, pathogens associated with both caries and 
periodontitis including Streptococcus mutans and Actinobacillus actinomycetemcomitas were 
demonstrated to be killed during in vitro studies which may demonstrate its potential anti-caries effect 
in a toothpaste (Jones, 2013).  
Despite the degree of research, there has been limited data supporting the clinical significance 
of the incorporation of these products and the use of BG as a method to deliver therapeutic ions, drugs 
or growth factors is still in its early stage of development. 
Bioactive glasses and Dentine Hypersensitivity 
According to the Hydrodynamic theory the resolution of any discomfort from DH would be based on 
the occlusion of the open dentinal tubules which would then limit or restrict the fluid flow through 
dentine. Since fluid flow is directly proportional to the fourth power of the radius as indicated by 
Poiseuille’s law, reduction of the radius of the tubule would subsequently reduce fluid flow and 
therefore reduce the stimulation of the mechanical receptors and nerve fibres (Lynch et al., 2012). Thus, 
halving the tubule radius would result in a 16 times decrease in fluid flow in the tubule. 
Consequently, there are two main mechanisms through which DH may be managed. The first 
mechanism, has been proposed to operate via Potassium ions, e.g., Potassium Nitrate (KNO3), 
Potassium Chloride or Potassium Citrate and as such does not involve tubule occlusion or affect fluid 
movements but rather targets the excitation of the nerve fibres. The increase in concentration of 
extracellular Potassium around the nerve fibres prevents their repolarization thereby blocking their 
excitation by inactivating their action potential (Wichgers and Emert, 1997). The second method 
involves occluding the exposed dentine tubules to produce a similar effect by preventing any stimuli 
5 
 
initiating fluid flow to trigger the mechanoreceptors. Absi et al., (1987) and Yoshiyama et al., (1989) 
identified that most dentine tubules were occluded in the non-sensitive dentine in the replica dies of 
patients examined clinically. BG toothpaste formulation would therefore be through this method of 
occluding tubules to relieve DH. The negative surface charge of the glass formed during its contact with 
water or saliva enables it to bind to the Type 1 collagen fibres found in dentine tubules (Greenspan, 
2010). The deposition of the HCA layer that forms following the surface reactions of the glass as well 
as the presence of residual BG particles result in the occlusion of the tubules (Salian et al., 2010). Gillam 
et al., (1997) stated that to treat DH via tubule occlusion was the logical conclusion from Brännström’s 
hydrodynamic theory. 
In Vitro Studies 
There is in vitro data supporting the ability of bioactive glasses, currently marketed under Sensodyne® 
toothpaste as Novamin®, to occlude dentinal tubules. For example, Gillam et al., (2002) demonstrated 
via SEM micrographs that the original Bioglass® was capable of partially occluding the tubules. 
However, more interestingly, it showed that when bioactive glasses were used to form a new toothpaste 
by replacing the silica component to different degrees, it was consistently more effective in occluding 
tubules. Tests were conducted on dentine discs from caries-free third molars comparing new toothpaste 
compositions containing 0%, 2.5% and 7.5% bioactive glass particles. Silica is the standard filler in 
most toothpastes, thus the replacement of silica with BG particles ensured the validity of the study as 
any differences demonstrated in the SEM images of the 2.5% and 7.5% toothpastes compared to the 
0% BG control must be due to the BG particles. All compositions showed a greater tubule occlusion 
than the original Bioglass® formulation with increased bioactive glass levels corresponding to 
significantly greater tubule occlusion due to increased particle deposition on the surface and within the 
tubules (Gillam et al., 2002).  
Particulate Bioglass® has been used for periodontal osseous repair using a size range of 70–
910 μm (Zamet et al., 1997) and 300–355 μm (Schepers & Ducheyne, 1997) and this original 45S5 
Bioglass® was initially used in the Gillam et al. study to determine its ability to occlude the dentinal 
tubules. However it was easily displaced by rinsing and handling and subsequently the investigators 
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incorporated the glass into standard toothpaste formulations to determine its effectiveness in occluding 
the tubules. Test dentine disc halves were treated with two Over-the-Counter toothpastes; Macleans 
Freshmint – a calcium carbonate-based paste (Smithkline Beecham, now GSK) and Elmex Amine 
Fluoride – an abrasive free paste (GABA, now Colgate), mixed in a ratio 5:1, toothpaste with the 
original Bioglass® material and three coded toothpaste products containing 0%, 2.5% and 7.5%. It was 
concluded from this study that BG particles in a suitable toothpaste formulation may be an effective 
way of treating DH. A study by Burwell et al., (2010) also demonstrated the ability of BG to occlude 
significant numbers of tubules. Mitchell et al., (2010) however, synthesised a bioactive glass 
formulation via a sol-gel synthesis instead of being melt-derived and as such had an increased surface 
area and chemical reactivity allowing for rapid bonding to the dentine surface. Additionally, they 
observed that BG immediately and continuously reduced the fluid conductance across the dentine for 
all time periods: 0hr, 1hr, 24hr, 96hr, and 168hr. The occluding deposits were maintained even after 
brushing of the prepared teeth and their soaking in acidic solutions of different pH for a minimum of 
seven days. Burwell et al., (2010) also supported Mitchell’s observations that the BG particles adhered 
to dentine and resisted an acid challenge. However, it should be noted that this study used bovine dentine 
rather than human dentine. Yassen et al., (2011) also observed that there was inconsistent data 
supporting the use of bovine teeth as an alternative to human teeth in erosion studies, for example, some 
studies suggested that there was greater wear, increased mineral loss and increased lesion depth in 
bovine teeth compared to human teeth whereas in other studies no differences between the two 
methodologies were observed. Burwell et al., (2010) also reported that Novamin® was able to provide 
a continuous release of Calcium which aided surface remineralization; whereas other calcium products 
would typically only provide an initial burst of calcium which would subsequently be diluted. Earl et 
al., (2011) confirmed that it was the development of a hydroxyapatite-like layer by the BG particles 
that occluded the tubules. Nevertheless it was apparent from the published literature that more research 
was required to determine the clinical effectiveness of Novamin® in the management of DH (Talioti et 
al., 2014). 
 In vitro studies have also been used to compare the effectiveness of different desensitizing 
agents on occluding the dentinal tubules. Using SEM imaging Joshi et al., (2013) demonstrated that 
7 
 
Novamin® resulted in greater numbers of completely occluded tubules than both the Gluma desensitizer 
and the control.  For example, the ratios of completely occluded tubules to total tubules were calculated: 
Novamin® scoring 0.545; Gluma scoring 0.402 and the control scoring 0.142, these results were 
statistically significant. Moreover, the Gluma desensitizer produced a layer of 1-2μm which occluded 
the tubules whereas Novamin® produced a thicker layer of 2-3μm. The clinical relevance of the thicker 
layer is important since a thicker layer would have the potential to reduce the fluid conductance in the 
tubules and be more resistant to acid/abrasive challenges although currently this concept has not been 
proven.  
 Further studies have demonstrated the benefits of different ionic compositions of bioactive 
glasses in its use as a dentifrice. Brauer et al., (2010) reported that fluoride containing glasses resulted 
in Fluorapatite (FAP) formation which is more acid resistant than HCA due to its lower Ka value which 
would suggest that incorporating bioactive glasses would provide a more effective dentifrice for treating 
DH. However, these investigators reported that high fluoride containing glasses mainly formed CaF2 in 
simulated body fluid (SBF). It was hypothesised that increasing the phosphate concentration would 
increase the Fluorapatite formation instead of CaF2 formation. This was confirmed by Mneimne et al., 
(2011) who compared 6 mol% phosphate BG to 1mol% phosphate BG and reported that an increased 
phosphate content did favour Fluorapatite instead of CaF2 formation in a Tris buffer solution. 
Furthermore, it was reported that increased phosphate levels resulted in a much more rapid apatite 
formation, within 6 hours for 6 mol% phosphate compared to within 3 days for 1 mol% phosphate 
concentration. A quicker rate of deposition would theoretically provide a faster relief from DH, and a 
greater acid resistance would lead to reduced removal of the apatite layer. It was suggested therefore 
that the use of a high phosphate content and fluoride containing BG would effectively provide a 
Fluorapatite formation which in turn would be more acid resistant than those dentifrices forming CaF2 
only. O’Donnell et al., (2009) further supported these results in a study and explained these results by 
suggesting that increasing the phosphate levels would in turn reduce the pH to a more near optimum 
level of 7.2 pH which is ideal for apatite deposition. Mohammed et al., (2013) refuted the claims of 
previous studies that CaF2 formation was beneficial due to its ability to exhibit an anti-caries effect; 
form a physical barrier on enamel surface; reduce rate of demineralization and act as a fluoride reservoir. 
8 
 
Instead these investigators reported that CaF2 formation reduced the Ca2+ available for remineralization 
which further resulted in loss of PO43- and concluded that CaF2 formation was “potentially detrimental” 
as it prevents apatite formation.  It was further noted that Strontium as well as Fluoride, both at 
concentrations 45ppm were capable of inhibiting the CaF2 formation.  However, the study only used 
static models not dynamic cyclic models which would have better mimicked the oral environment. 
Moreover, an increase in Ca2+ and PO43- deposition may also lead to an increase in calculus formation. 
Nonetheless, the addition of Fluoride to BG’s was concluded to be beneficial to oral health (Brauer et 
al., 2009). 
Abrasivity 
Ali et al., (2012) identified that BG used in a dentifrice e.g. Novamin® based on the 45S5 glass was 
significantly harder than enamel and dentine (Table 3). This data, together with other data would suggest 
that some BGs could have a Mohs hardness value of 7 GPa or more. However, this figure should ideally 
be below 3.5 GPa, which is the hardness of enamel, in order to prevent any tooth wear. These 
investigators also noted that the Fluoride and Strontium addition would result in a reduction of both 
hardness and abrasivity values which would be highly beneficial to be incorporated in a BG dentifrice. 
There are however limited and contradictory data analysing the abrasivity of BG in the published 
literature which also suggests the need for further work in this area. Additionally, Ali et al., (2012) 
indicated that there was a lack of evidence in the literature on the effect of salivary proteins on apatite 
deposition and emphasized the need for further research into this area.  
Table 3 Mohs harness values in selected materials and structures 




Calcium Carbonate 3.0 
Alumina 9.25 
 
There are also limited data on the particle size and shape and relative abrasivity of bioactive 
glass particles and it has been previously reported that particles that were more rounded and less 
angular could be expected to have a reduced abrasivity and a direct correlation was observed between 
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both particle size and abrasivity.  LaTorre et al., (2010) also demonstrated that finer particle sizes of 
Calcium Sodium Phosphosilicates (CSPS) resulted in a greater Ca2+ and PO43- deposition. However, 
these studies were conducted in vitro and ideally in vivo studies are required since these variables would 
be considerably different in a final formulation (Ali et al., 2012). This would be particularly relevant 
for research into the effect on abrasion (by tooth brushing) following an acid challenge. Furthermore, 
as in vitro studies generally use healthy or unerupted teeth for SEM investigation, clinically teeth 
exposed to the norms of daily life may exhibit tooth wear and the thickness of the enamel may be 
reduced. This is evident particularly in the cervical area of the tooth where the enamel is at its thinnest 
and the dentine may be exposed. Ideally in vitro studies need to mimic the normal oral environment but 
sometimes this is very difficult to achieve for a number of reasons and care should be taken not to 
extrapolate these results in vitro studies into the clinical environment. It was also apparent that further 
investigation was required to analyse both particle size and shape in order to reduce abrasivity.  For 
example, Mahmood et al., (2014) reported that increased particle size resulted in a greater enamel loss 
when comparing three different particle sizes of BG dentifrices: <38, 38-63 and 63-110 microns. 
Particles formed from percussion milling with sharp edges were reported to be significantly more 
abrasive than round ball milled particles. Preferential wear was observed at the Enamel Dentine 
Junction; considering that this area relevant for both gingival recession and DH, it would be worthwhile 
to reduce the abrasivity of the dentifrice as much as possible otherwise greater wear will occur in the 
cervical area of the tooth. These investigators concluded that the abrasivity of a BG dentifrice was not 
a major problem, nevertheless, it is still advantageous to lower the abrasivity component especially 
when considering that the Fluorapatite layer formed is thin and can potentially be removed via abrasion 
[35]. Abrasives in a dentifrice can however contribute to the removal of tooth substance and initiate DH 
and as such it should be recommended to have a low abrasive toothpaste which will minimise tooth 
surface loss while being able to remove stain and plaque from the tooth surface.  
The original Novamin® dentifrice did not contain strontium, and Ali et al., (2012) suggested 
that it would be advantageous to include Strontium in BG dentifrice due to its anti-caries effect, ability 
in remineralization and apatite formation; and help to reduce the abrasivity of a dentifrice. Studies 
specifically comparing Strontium containing Bioactive glasses to non-strontium containing dentifrices 
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should be conducted in vitro and in vivo to determine whether the incorporation of Strontium into a 
dentifrice is relevant  and clinical relevant. Further research analysing different ionic compositions of 
bioactive glass dentifrices including different concentrations of Strontium, Fluoride, Zinc and other ions 
(Table 2) should therefore by conducted to determine the optimum concentration to be used in a 
bioactive glass dentifrice to treat DH. 
In Vivo Studies 
Litkowski et al., (2010) conducted a proof of principle study to test the bioactive glass’s safety in vivo 
and to assess whether the in vitro occlusion of dentinal tubules translated to a clinically significant 
reduction in DH. This randomized, double-blinded study compared the following interventions namely 
2.5% Novamin®, 7.5% Novamin® and a placebo (0% Bioglass) dentifrice formulations. Using thermal 
air and tactile tests on 66 subjects, the Novamin® dentifrices resulted in a statistically significant greater 
reduction in sensitivity scores compared to the placebo. The 7.5% Novamin® formulation resulted in 
the greatest reduction with no adverse events reported which appeared to support the use of a Novamin® 
dentifrice to relieve DH. The clinical evidence was supported by Gillam et al., (2002) in an in vitro 
study where the same interventions were evaluated under SEM investigation in that the 7.5% 
Novamin® occluded most of the tubules compared to 2.5% and 0% Novamin® which provided 
evidence of the potential mechanism (tubule occlusion) of the Novamin® dentifrice formulation. 
Gendreau et al, (2011) also provided a comprehensive summary of previous in vivo studies. In all the 
studies reviewed by Gendreau et al, (2011), Novamin® consistently resulted in a significantly greater 
reduction in all sensitivity tests compared to either a placebo or other dentifrices. However, the Talioti 
et al., (2014) systematic review identified the various biases present in many of these and other studies. 
For example, Litkowski et al., (2010) failed to provide any information concerning their randomization 
process or allocation concealment nevertheless, their study was still included in the Talioti et al., review 
unlike the Salian et al., (2010) study which was excluded due to its negative control group containing 
Fluoride whereas the intervention group, Novamin®, did not contain Fluoride. Du et al., (2008) study 
was also excluded since it only provided an abstract. Studies that were only reported as an abstract 
were also excluded Pradeep et al., 2012 and Pradeep and Sharma, (2010) were also considered of a 
high quality and fitted the inclusion criteria to be incorporated in the review. However, Pradeep et al., 
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(2012) did not disclose any information concerning calibration over the measure of DH and failed to 
sufficiently describe the placebo group. Additionally, Pradeep and Sharma, (2010) did not provide any 
further details regarding their randomization method which was performed via a lottery process.  Most 
of the studies obtained in the search strategy, however, were excluded by Talioti et al. [1]. For 
example, 31/34 Novamin® studies were excluded and the reasons for exclusion were extensive, the 
investigators also commented on the heterogeneity between the various studies which made further 
analysis impossible. Overall, the Talioti et al., 2014 review included only three randomized controlled 
trials involving CSPS. Although randomized controlled trials are a high level of evidence, the small 
number of included studies rendered it impossible to make any definitive conclusions on the efficacy 
of Novamin® for treating DH. According to these investigators there was a need for further high quality 
studies in order to assess the effects of Novamin® formulations. It was evident that the current 
Novamin® products contain 5% CSPS although Litkowski et al., (2010) clearly showed that the 7.5% 
formulation was more efficacious than the 2.5% formulation. There were, however limited data on 
studies comparing the various concentrations of bioactive glasses based on the Novamin® patent but 
one possible reason for using the lower percentage of glass in the formulation was the cost of the glass 
particles.  
Several studies have recently compared a Novamin® formulation with Potassium Nitrate (5% KNO3) 
dentifrice formulations, for example, Acharya et al., (2013) compared a 5% CSPS dentifrice to a 5% 
KNO3 dentifrice. It was reported that although the 5% CSPS group did result in a lower VAS score after 
2 weeks of use, there were no statistically significant differences between the two groups at 4 and 8 
weeks. Satyapal et al., (2014) also compared 5% CSPS to 5% KNO3 and reported that the CSPS group 
resulted in a statistically significant lower VAS scores after 3 weeks. The 60 participants were 
subsequently asked to discontinue using the dentifrice and then recalled after a further 3 weeks. The 
VAS scores increased following this discontinuation however, the 5% CSPS group still scored 
significantly less than the 5% KNO3 group after the total of 6 weeks. One of the problems of this 
randomised single-blind study was the limited duration of the study involving only one time point that 
was measured. Ideally a longer duration study with assessments at multiple time points during use and 
following discontinuation would be preferred.  Study design is often a problem when evaluating clinical 
12 
 
studies and it is important for investigators to follow the published guidelines on conducting studies 
when testing desensitising dentifrice formulations (Holland et al. 1997). For example, Morris et al., 
(1999) highlighted the need for large sample sizes due to the immense placebo effect present in DH 
studies.  A further problem in this field is the lack of a so-called gold standard product to compare in 
these types of studies (Porto et al., 2009) and although some investigators have used of KNO3 dentifrice 
formulations in this way there is no evidence to support the use of KNO3 dentifrices in treating DH 
(Poulson et al., 2006, Karim and Gillam 2013).  
Conclusions  
Although the exact number of individuals suffering DH is controversial, it is undoubtedly a significant 
proportion of the population that complain about the problem. Overall, there appears to be promising 
evidence supporting the use of bioactive glasses to treat DH. In vitro evidence supports the ability of 
CSPS to occlude dentinal tubules whereas currently there appears to be limited in vivo evidence to 
support its efficacy in alleviating DH. There are also limited data in the published literature on the exact 
loading of CSPS glass into dentifrice formulations, abrasivity of CSPS, particle size and shape and the 
incorporations of various ions such as strontium and active ingredients into the bioactive glass’ network 
structure.  
References 
1. Absi, E., Addy, M. and Adams, D. (1987). Dentine hypersensitivity. A study of the patency of 
dentinal tubules in sensitive and non-sensitive cervical dentine. Journal of Clinical 
Periodontology, 14(5), pp.280-284. 
2. Acharya, A., Surve, S. and Thakur, S. (2013). A clinical study of the effect of calcium sodium 
phosphosilicate on dentin hypersensitivity. Journal of Clinical and Experimental Dentistry, 
pp.e18-22. 
3. Ali, S., Hill, R. and Gillam, D. (2012). Dentine Hypersensitivity and Abrasivity of Bioactive 
Glass Toothpaste. LAP LAMBERT Academic Publishing.  
4. Ali, S., Farooq, I. and Iqbal, K. (2014). A review of the effect of various ions on the properties 
and the clinical applications of novel bioactive glasses in medicine and dentistry. The Saudi 
Dental Journal, 26(1), pp.1-5.  
5. Brännström M, Aström A. (1972). The hydrodynamics of the dentine; its possible relationship 
to dentinal pain. Int Dent J 22(2), pp.219-27. 
6. Brauer, D., Karpukhina, N., O’Donnell, M., Law, R. and Hill, R. (2010). Fluoride-containing 
bioactive glasses: Effect of glass design and structure on degradation, pH and apatite formation 
in simulated body fluid. Acta Biomaterialia, 6(8), pp.3275-3282. 
7. Burwell, A., Jennings, D., Muscle, D. and Greenspan, D. (2010). NovaMin and dentin 
hypersensitivity--in vitro evidence of efficacy. J Clin Dent, 21(3), pp.66-71. 
13 
 
8. Schepers and Ducheyne P. (1997) Bioactive glass particles of narrow size range for the 
treatment of oral bone defects: a 1–24 month experiment with several materials and particle 
sizes and size ranges. Journal of Oral Rehabilitation, 24, 171171. 
9. Earl, J., Leary, R., Muller, K., Langford, R. and Greenspan, D. (2011). Physical and chemical 
characterization of dentin surface following treatment with NovaMin technology. J Clin Dent, 
22(3), pp.62-67. 
10. Gendreau, L., Barlow, A. and Mason, S. (2011). Overview of the clinical evidence for the use 
of NovaMin in providing relief from the pain of dentin hypersensitivity. J Clin Dent, 22(3), 
pp.90-95. 
11. Gentleman, E., Stevens, M., Hill, R. and Brauer, D. (2013). Surface properties and ion release 
from fluoride-containing bioactive glasses promote osteoblast differentiation and 
mineralization in vitro. Acta Biomaterialia, 9(3), pp.5771-5779.  
12. Gillam, D. (1997). Clinical trial designs for testing of products for dentine hypersensitivity-a 
review. J West Soc Periodontol Periodontal Abstr, 45(2), pp.37-46. 
13. Gillam, D., Tang, J., Mordan, N. and Newman, H. (2002). The effects of a novel Bioglass® 
dentifrice on dentine sensitivity: a scanning electron microscopy investigation. J Oral Rehabil, 
29(4), pp.305-313. 
14. Gillam, D., Bulman, J., Eijkman, M. and Newman, H. (2002). Dentists' perceptions of dentine 
hypersensitivity and knowledge of its treatment. J Oral Rehabil, 29(3), pp.219-225. 
15. Greenspan, D. (2010). NovaMin and tooth sensitivity--an overview. J Clin Dent, 21(3), pp.61-
65. 
16. Hench, L., Splinter, R., Allen, W., Greenlee, T. (1972). Bonding mechanisms at the interface 
of ceramic prosthetic materials. J Biomed Mater Res 2:117–141.  
17. Hench, L. and Wilson, J. An Introduction to Bioceramics. Singapore, World Scientific 
Publishing, 1993. 
18. Hench, L. (1998). Bioceramics. Journal of the American Ceramic Society, 81(7), pp.1705-
1728. 
19. Hench, L. (2006). The story of Bioglass®. J Mater Sci: Mater Med, 17(11), pp.967-978.  
20. Hench, L. (2013). Chronology of bioactive glass development and clinical applications. New 
J. Glass Ceram, 3(2), pp.67–73. 
21. Holland, G., Narhi, M., Addy, M., Gangarosa, L. and Orchardson, R. (1997). Guidelines for 
the design and conduct of clinical trials on dentine hypersensitivity*. Journal of Clinical 
Periodontology, 24(11), pp.808-813. 
22. Jell, G. and Stevens, M. (2006). Gene activation by bioactive glasses. J Mater Sci: Mater Med, 
17(11), pp.997-1002.  
23. Jones, J. (2013). Review of bioactive glass: From Hench to hybrids. Acta Biomaterialia, 9(1), 
pp.4457-4486.  
24. Joshi, S., Shivananje Gowda, A. and Joshi, C. (2013). Comparative evaluation of NovaMin 
desensitizer and Gluma desensitizer on dentinal tubule occlusion: a scanning electron 
microscopic study. J Periodontal Implant Sci, 43(6), p.269.  
25. Karim, B. and Gillam, D. (2013). The Efficacy of Strontium and Potassium Toothpastes in 
Treating Dentine Hypersensitivity: A Systematic Review. International Journal of Dentistry, 
2013, pp.1-13. 
26. Kaur, G., Pandey, O., Singh, K., Homa, D., Scott, B. and Pickrell, G. (2013). A review of 
bioactive glasses: Their structure, properties, fabrication and apatite formation. Journal of 
Biomedical Materials Research Part A, 102(1), pp.254-274.  
27. LaTorre, G. and Greenspan, D. (1600). The role of ionic release from NovaMin (calcium 
sodium phosphosilicate) in tubule occlusion: an exploratory in vitro study using radio-labeled 
isotopes. J Clin Dent, 21(3), pp.72-76. 
14 
 
28. Litkowski, L. and Greenspan, D. (2010). A clinical study of the effect of calcium sodium 
phosphosilicate on dentin hypersensitivity-proof of principle. J Clin Dent, 21(3), pp.77-81. 
29. Lockyer, M., Holland, D. and Dupree, R. (1995). NMR investigation of the structure of some 
bioactive and related glasses. Journal of Non-Crystalline Solids, 188(3), pp.207-219.   
30. Lynch, E., Brauer, D., Karpukhina, N., Gillam, D. and Hill, R. (2012). Multi-component 
bioactive glasses of varying fluoride content for treating dentin hypersensitivity. Dental 
Materials, 28(2), pp.168-178. 
31. Mahmood, A., Mneimne, M., Zou, L., Hill, R. and Gillam, D. (2014). Abrasive wear of enamel 
by bioactive glass-based toothpastes. Am J Dent, 27(5), pp.263-267. 
32. Miglani, S., Aggarwal, V. and Ahuja, B. (2010). Dentin hypersensitivity: Recent trends in 
management. Journal of Conservative Dentistry, 13(4), p.218.  
33. Mitchell, J., Musanje, L. and Ferracane, J. (2011). Biomimetic dentin desensitizer based on 
nano-structured bioactive glass. Dental Materials, 27(4), pp.386-393. 
34. Mneimne, M., Hill, R., Bushby, A. and Brauer, D. (2011). High phosphate content significantly 
increases apatite formation of fluoride-containing bioactive glasses. Acta Biomaterialia, 7(4), 
pp.1827-1834.  
35. Mohammed, N., Kent, N., Lynch, R., Karpukhina, N., Hill, R. and Anderson, P. (2013). Effects 
of Fluoride on in vitro Enamel Demineralization Analyzed by 19F MAS-NMR. Caries Res, 
47(5), pp.421-428. 
36. Morris, M., Davis, R. and Richardson, B. (2016). Clinical efficacy of two dentin desensitizing 
agents. Am J Dent, 12(2), pp.72-76. 
37. O’Donnell, M., Watts, S., Hill, R. and Law, R. (2009). The effect of phosphate content on the 
bioactivity of soda-lime-phosphosilicate glasses. J Mater Sci: Mater Med, 20(8), pp.1611-
1618. 
38. Pradeep AR, Sharma A. (2010). Comparison of clinical efficacy of a dentifrice containing 
calcium sodium phosphosilicate to a dentifrice containing potassium nitrate and to a placebo 
on dentinal hypersensitivity: a randomized clinical trial. Journal of Periodontology, 
81(8):1167–1173. 
39. Pradeep AR, Agarwal E, Naik SB, Bajaj P, Kalra N.(2012). Comparison of efficacy of three 
commercially available dentifrices on dentinal hypersensitivity: a randomized clinical 
trial. Australian Dental Journal, 57(4):429–434.  
40. Porto, I., Andrade, A. and Montes, M. (2016). Diagnosis and treatment of dentinal 
hypersensitivity. Journal of Oral Science, 51(3), pp.323-332. 
41. Satyapal, T., Mali, R., Mali, A. and Patil, V. (2014). Comparative evaluation of a dentifrice 
containing calcium sodium phosphosilicate to a dentifrice containing potassium nitrate for 
dentinal hypersensitivity: A clinical study. Journal of Indian Society of Periodontology, 18(5), 
p.581. 
42. Shi, D. (2004). Biomaterials and tissue engineering. Berlin: Springer-Verlag Berlin 
Heidelberg. 
43. Talioti, E., Hill, R. and Gillam, D. (2014). The Efficacy of Selected Desensitizing OTC 
Products: A Systematic Review. ISRN Dentistry, 2014, pp.1-14.  
44. Walters, P. (2014). Dentinal Hypersensitivity: A Review. [Online] Available at: 
http://www.dentalcare.com/media/en-US/education/ce200/ce200.pdf [Accessed 30 Jan 2016] 
45. Wichgers, T. and Emert, R. (1997). Dentin Hypersensitivity. Oral Health, 87(3), pp.51-56.
  
46. Wu, C. and Chang, J. (2014). Multifunctional mesoporous bioactive glasses for effective 




47. West, N., Lussi, A., Seong, J. and Hellwig, E. (2012). Dentin hypersensitivity: pain mechanisms 
and aetiology of exposed cervical dentin. Clin Oral Invest, 17(S1), pp.9-19. 
48. Yassen, G., Platt, J. and Hara, A. (2011). Bovine teeth as substitute for human teeth in dental 
research: a review of literature. J Oral Sci, 53(3), pp.273-282. 
49. Yoshiyama, M., Masada, J., Uchida, A. and Ishida, H. (1989). Scanning Electron Microscopic 
Characterization of Sensitive vs. Insensitive Human Radicular Dentin. Journal of Dental 
Research, 68(11), pp.1498-1502.  
50. Zamet J.S., Darbar, U., Griffiths, G.S., Bulman, J.S., Bragger, U., Burgin, W., and Newman, 
H.N. (1997) Particulate bioglass as a grafting material in the treatment of periodontal intrabony 
defects. Journal of Clinical Periodontology, 24, 410410. 
